Biology and genetics of prions causing neurodegeneration

Annual Review of Genetics

Volumn 47, Issue , 2013, Pages 601-623

  Prusiner, Stanley B ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Neurodegeneration; Prion

Indexed keywords

ALPHA SYNUCLEIN; AMYLOID BETA PROTEIN; COPPER ZINC SUPEROXIDE DISMUTASE; FUNGAL PROTEIN; HUNTINGTIN; OLIGOMER; PRION PROTEIN; PROGRANULIN; TAR DNA BINDING PROTEIN; TAU PROTEIN;

ALZHEIMER DISEASE; AMYLOID PLAQUE; AMYOTROPHIC LATERAL SCLEROSIS; BETA SHEET; CREUTZFELDT JAKOB DISEASE; DEGENERATIVE DISEASE; GENE MUTATION; HUMAN; NERVE DEGENERATION; NEUROFIBRILLARY TANGLE; NONHUMAN; PARKINSON DISEASE; PATHOGENESIS; PRION; PRIORITY JOURNAL; PROTEIN AGGREGATION; PROTEIN CONFORMATION; PROTEIN FUNCTION; REVIEW; TAUOPATHY;

FUNGI; MAMMALIA;

AGE OF ONSET; AMYLOIDOGENIC PROTEINS; ANIMALS; FUNGAL PROTEINS; HUMANS; INCLUSION BODIES; MAMMALS; MODELS, MOLECULAR; MRNA CLEAVAGE AND POLYADENYLATION FACTORS; NEURODEGENERATIVE DISEASES; NEUROFIBRILLARY TANGLES; PEPTIDE TERMINATION FACTORS; PLAQUE, AMYLOID; PRION DISEASES; PRIONS; PROTEIN CONFORMATION; SACCHAROMYCES CEREVISIAE PROTEINS; SYNUCLEINS; TAU PROTEINS; TAUOPATHIES; TRANSCRIPTION FACTORS; VIRULENCE;

EID: 84888594143     PISSN: 00664197     EISSN: 15452948     Source Type: Book Series    
DOI: 10.1146/annurev-genet-110711-155524     Document Type: Review

References (205)

1. Alper T, Haig DA, Clarke MC. 1966. The exceptionally small size of the scrapie agent. Biochem. Biophys. Res. Commun. 22:278-84
2. Alzheimer A. 1907. Ueber eine eigenartige Erkrankung der Hirnrinde. Cent. Nervenheilk. Psychiat. 30:177-79
3. Ash PE, Bienik KF, Gendron TF, Caulfield T, Lin WL, et al. 2013. Unconventional translation of C9ORF72 GGGGCC expansion generates insoluble polypeptides specific to c9FTD/ALS. Neuron 77:639-46
4. Baker HF, Ridley RM, Duchen LW, Crow TJ, Bruton CJ. 1994. Induction of ß(A4)-amyloid in primates by injection of Alzheimer's disease brain homogenate. Mol. Neurobiol. 8: 25-39
5. Baskakov IV, Legname G, Baldwin MA, Prusiner SB, Cohen FE. 2002. Pathway complexity of prion protein assembly into amyloid. J. Biol. Chem. 277:21140-48
6. Bellinger-Kawahara CG, Kempner E, Groth DF, Gabizon R, Prusiner SB. 1988. Scrapie prion liposomes and rods exhibit target sizes of 55, 000 Da. Virology 164:537-41
7. Benilova I, Karran E, De Strooper B. 2012. The toxic Aβoligomer and Alzheimer's disease: an emperor in need of clothes. Nat. Neurosci. 15:349-57
8. Bernoulli C, Siegfried J, Baumgartner G, Regli F, Rabinowicz T, et al. 1977. Danger of accidental person-to-person transmission of Creutzfeldt-Jakob disease by surgery. Lancet 309:478-79
9. Bithell A, Johnson R, Buckley NJ. 2009. Transcriptional dysregulation of coding and non-coding genes in cellular models of Huntington's disease. Biochem. Soc. Trans. 37:1270-75
10. Bolton DC, McKinley MP, Prusiner SB. 1982. Identification of a protein that purifies with the scrapie prion. Science 218:1309-11
11. Braak H, Braak E. 1995. Staging of Alzheimer's disease-related neurofibrillary changes. Neurobiol. Aging 16:271-84
12. Braak H, Braak E, Yilmazer D, de Vos RA, Jansen EN, Bohl J. 1996. Pattern of brain destruction in Parkinson's and Alzheimer's diseases. J. Neural Transm. 103:455-90
13. Braak H, Del Tredici K. 2011. Alzheimer's pathogenesis: Is there neuron-to-neuron propagation? Acta Neuropathol. 121:589-95
14. Braak H, Rub U, Gai WP, Del Tredici K. 2003. Idiopathic Parkinson's disease: possible routes by which vulnerable neuronal types may be subject to neuroinvasion by an unknown pathogen. J. Neural Transm. 110:517-36
15. Brion J-P, Passareiro H, Nunez J, Flament-Durand J. 1985. Mise en évidence immunologique de la protéine tau au niveau des lésions de dégénérescence neurofibrillaire de la maladie d'Alzheimer. Arch. Biol. 95:229-35
16. Browning SR, Mason GL, Seward T, Green M, Eliason GA, et al. 2004. Transmission of prions from mule deer and elk with chronic wasting disease to transgenic mice expressing cervid Pr P. J. Virol. 78:13345-50
17. Bruce ME, Dickinson AG. 1985. Genetic control of amyloid plaque production and incubation period in scrapie-infected mice. J. Neuropathol. Exp. Neurol. 44:285-94
18. Castellano JM, Kim J, Stewart FR, Jiang H, DeMattos RB, et al. 2011. Human apoE isoforms differentially regulate brain amyloid-β peptide clearance. Sci. Transl. Med. 3:89ra57
19. Chapman J, Ben-Israel J, Goldhammer Y, Korczyn AD. 1994. The risk of developing Creutzfeldt-Jakob disease in subjects with the PRNP gene codon 200 point mutation. Neurology 44:1683-86
20. Chen Y-C, Prescott CA, Walsh D, Patterson DG, Riley BP, et al. 2011. Different phenotypic and genotypic presentations in alcohol dependence: age at onset matters. J. Stud. Alcohol Drugs 72:752-62
21. Chien P, Weissman JS, DePace AH. 2004. Emerging principlesofconformation- based prion inheritance. Annu. Rev. Biochem. 73:617-56
22. Clavaguera F, Bolmont T, Crowther RA, Abramowski D, Frank S, et al. 2009. Transmission and spreading of tauopathy in transgenic mouse brain. Nat. Cell Biol. 11:909-13
23. Cohen RM, Rezai-Zadeh K, Weitz TM, Rentsendorj A, Gate D, et al. 2013. A transgenic Alzheimer rat with plaques, tau pathology, behavioral impairment, oligomeric Aβ, and frank neuronal loss. J. Neurosci. 33:6245-56
24. Colby DW, Giles K, Legname G, Wille H, Baskakov IV, et al. 2009. Design and construction of diverse mammalian prion strains. Proc. Natl. Acad. Sci. USA 106:20417-22
25. Corsellis JA, Bruton CJ, Freeman-Browne D. 1973. The aftermath of boxing. Psychol. Med. 3:270-303
26. Corti O, Lesage S, Brice A. 2011. What genetics tells us about the causes and mechanisms of Parkinson's disease. Physiol. Rev. 91:1161-218
27. Coskun PE, Wyrembak J, Derbereva O, Melkonian G, Doran E, et al. 2010. Systemic mitochondrial dysfunction and the etiology of Alzheimer's disease and Down syndrome dementia. J. Alzheimers Dis. 20(Suppl. 2):S293-310
28. Croes EA, Theuns J, Houwing-Duistermaat JJ, Dermaut B, Sleegers K, et al. 2004. Octapeptide repeat insertions in the prion protein gene and early onset dementia. J. Neurol. Neurosurg. Psychiatry 75:1166-70
29. de Calignon A, Polydoro M, Suarez-Calvet M, William C, Adamowicz DH, et al. 2012. Propagation of tau pathology in a model of early Alzheimer's disease. Neuron 73:685-97
30. DeMattos RB, Lu J, Tang Y, Racke MM, DeLong CA, et al. 2012. A plaque-specific antibody clears existing β-amyloid plaques in Alzheimer's disease mice. Neuron 76:908-20
31. Deutschbauer AM, Jaramillo DF, Proctor M, Kumm J, Hillenmeyer ME, et al. 2005. Mechanisms of haploinsufficiency revealed by genome-wide profiling in yeast. Genetics 169:1915-25
32. Divry P. 1927. Etude histochimique des plaques seniles. J. Belge Neurol. Psychiatr. 27:643-54
33. Dlouhy SR, Hsiao K, Farlow MR, Foroud T, Conneally PM, et al. 1992. Linkage of the Indiana kindred of Gerstmann-Sträussler-Scheinker disease to the prion protein gene. Nat. Genet. 1:64-67
34. Dobson CM. 2003. Protein folding and misfolding. Nature 426:884-90
35. Eisele YS, Bolmont T, Heikenwalder M, Langer F, Jacobson LH, et al. 2009. Induction of cerebral β-amyloidosis: intracerebral versus systemic Aβ inoculation. Proc. Natl. Acad. Sci. USA 106:12926-31
36. Eisele YS, Obermuller U, Heilbronner G, Baumann F, Kaeser SA, et al. 2010. Peripherally applied Aβ-containing inoculates induce cerebral beta-amyloidosis. Science 330:980-82
37. Eisenberg D, Jucker M. 2012. The amyloid state of proteins in human diseases. Cell 148:1188-203
38. Eklund CM, Hadlow WJ, Kennedy RC. 1963. Some properties of the scrapie agent and its behavior in mice. Proc. Soc. Exp. Biol. Med. 112:974-79
39. Fraser H. 1982. Neuronal spreadofscrapie agent and targetingoflesions within the retino-tectal pathway. Nature 295:149-50
40. Fraser H, Dickinson AG. 1968. The sequential development of the brain lesions of scrapie in three strains of mice. J. Comp. Pathol. 78:301-11
41. Frost B, Jacks RL, Diamond MI. 2009. Propagation of tau misfolding from the outside to the inside of a cell. J. Biol. Chem. 284:12845-52
42. Gabizon R, Rosenmann H, Meiner Z, Kahana I, Kahana E, et al. 1993. Mutation and polymorphism of the prion protein gene in Libyan Jews with Creutzfeldt-Jakob disease (CJD). Am. J. Hum. Genet. 53:828-35
43. Gajdusek DC. 1977. Unconventional viruses and the origin and disappearance of kuru. Science 197:943-60
44. Gajdusek DC, Gibbs CJ Jr, Alpers M. 1966. Experimental transmission of a kuru-like syndrome to chimpanzees. Nature 209:794-96
45. Games D, Adams D, Alessandrini R, Barbour R, Berthelette P, et al. 1995. Alzheimer-type neuropathol-ogy in transgenic mice overexpressing V717F β-amyloid precursor protein. Nature 373:523-27
46. Ghaemmaghami S, Colby DW, Nguyen H-OB, Hayashi S, DeArmond SJ, Prusiner SB. 2013. Convergent replication of synthetic mouse prion strains. Am. J. Pathol. 182(3):866-74
47. Ghaemmaghami S, Watts JC, Nguyen H-O, Hayashi S, DeArmond SJ, Prusiner SB. 2011. Conforma-tional transformation and selection of synthetic prion strains. J. Mol. Biol. 413:527-42
48. Giasson BI, Duda JE, Quinn SM, Zhang B, Trojanowski JQ, Lee VM. 2002. Neuronal α-synucleinopathy with severe movement disorder in mice expressing A53T human α-synuclein. Neuron 34:521-33
49. Gibbs CJ Jr, Gajdusek DC, Asher DM, Alpers MP, Beck E, et al. 1968. Creutzfeldt-Jakob disease (spongiform encephalopathy): transmission to the chimpanzee. Science 161:388-89
50. Giles K, De Nicola GF, Patel S, Glidden DV, Korth C, et al. 2012. Identifying I137M and other mutations that modulate incubation periods for two human prion strains. J. Virol. 86:6033-41
51. Giles K, Glidden DV, Beckwith R, Seoanes R, Peretz D, et al. 2008. Resistance of bovine spongiform encephalopathy (BSE) prions to inactivation. PLoS Pathog. 4:e1000206
52. Gilks N, Kedersha N, Ayodele M, Shen L, Stoecklin G, et al. 2004. Stress granule assembly is mediated by prion-like aggregation of TIA-1. Mol. Biol. Cell. 15:5383-98
53. Glenner GG, Eanes ED, Bladen HA, Linke RP, Termine JD. 1974. Beta-pleated sheet fibrils: a comparison of native amyloid with synthetic protein fibrils. J. Histochem. Cytochem. 22:1141-58
54. Glenner GG, Wong CW. 1984. Alzheimer's disease and Down's syndrome: sharing of a unique cere-brovascular amyloid fibril protein. Biochem. Biophys. Res. Commun. 122:1131-35
55. Glenner GG, Wong CW. 1984. Alzheimer's disease: initial reportofthe purification and characterization of a novel cerebrovascular amyloid protein. Biochem. Biophys. Res. Commun. 120:885-90
56. Goate A, Chartier-Harlin M-C, Mullan M, Brown J, Crawford F, et al. 1991. Segregation of a missense mutation in the amyloid precursor protein gene with familial Alzheimer's disease. Nature 349:704-6
57. Godec MS, Asher DM, Masters CL, Kozachuk WE, Friedland RP, et al. 1991. Evidence against the transmissibility of Alzheimer's disease. Neurology 41:1320
58. Goudsmit J, Morrow CH, Asher DM, Yanagihara RT, Masters CL, et al. 1980. Evidence for and against the transmissibility of Alzheimer's disease. Neurology 30:945-50
59. Grad LI, Guest WC, Yanai A, Pokrishevsky E, O'Neill MA, et al. 2011. Intermolecular transmission of superoxide dismutase 1 misfolding in living cells. Proc. Natl. Acad. Sci. USA 108:16398-403
60. Greenfield JG, Matthews WB. 1954. Post-encephalitic parkinsonism with amyotrophy. J. Neurol. Neu-rosurg. Psychiatry 17:50-56
61. Greenwald J, Buhtz C, Ritter C, Kwiatkowski W, Choe S, et al. 2010. The mechanism of prion inhibition by HET-S. Mol. Cell 38:889-99
62. Grundke-Iqbal I, Iqbal K, Tung Y-C, Quinlan M, Wisniewski HM, Binder LI. 1986. Abnormal phos-phorylation of the microtubule-associated protein (tau) in Alzheimer cytoskeletal pathology. Proc. Natl. Acad. Sci. USA 83:4913-17
63. Guo JL, Lee VM-Y. 2011. Seeding of normal tau by pathological tau conformers drives pathogenesis of Alzheimer-like tangles. J. Biol. Chem. 286:15317-31
64. Hadlow WJ. 1959. Scrapie and kuru. Lancet 274:289-90
65. Hadlow WJ, Eklund CM, Kennedy RC, Jackson TA, Whitford HW, Boyle CC. 1974. Course of experimental scrapie virus infection in the goat. J. Infect. Dis. 129:559-67
66. Halfmann R, Jarosz DF, Jones SK, Chang A, Lancaster AK, Lindquist S. 2012. Prions are a common mechanism for phenotypic inheritance in wild yeasts. Nature 482:363-68
67. Hardy J, Cai H, Cookson MR, Gwinn-Hardy K, Singleton A. 2006. Genetics of Parkinson's disease and parkinsonism. Ann. Neurol. 60:389-98
68. Hardy J, Revesz T. 2012. The spread of neurodegenerative disease. N. Engl. J. Med. 366:2126-28
69. Hardy J, Selkoe DJ. 2002. The amyloid hypothesis of Alzheimer's disease: progress and problems on the road to therapeutics. Science 297:353-56
70. Harold D, Abraham R, Hollingworth P, Sims R, Gerrish A, et al. 2009. Genome-wide association study identifies variants at CLU and PICALM associated with Alzheimer's disease. Nat. Genet. 41:1088-93
71. Health Protection Agency. 2009. Variant CJD and plasma products. London: Public Health Engl. http://www.hpa.org.uk/webw/HPAweb&HPAwebStandard/HPAweb- C/1195733818681? p=1225960597236
72. Healy DG, Falchi M, O'Sullivan SS, Bonifati V, Durr A, et al. 2008. Phenotype, genotype, and worldwide genetic penetrance of LRRK2-associated Parkinson's disease: a case-control study. Lancet Neurol. 7:583-90
73. Hewitt PE, Llewelyn CA, Mackenzie J, Will RG. 2006. Creutzfeldt-Jakob disease and blood transfusion: results of the UK Transfusion Medicine Epidemiological Review study. Vox Sang. 91:221-30
74. Hoge CW, McGurk D, Thomas JL, Cox AL, Engel CC, Castro CA. 2008. Mild traumatic brain injury in U.S. soldiers returning from Iraq. N. Engl. J. Med. 358:453-63
75. Holmes BB, Diamond MI. 2012. Amyotrophic lateral sclerosis and organ donation: Is there risk of disease transmission? Ann. Neurol. 72:832-36
76. Hong M, Zhukareva V, Vogelsberg-Ragaglia V, Wszolek Z, Reed L, et al. 1998. Mutation-specific functional impairments in distinct tau isoforms of hereditary FTDP-17. Science 282:1914-17
77. Hou F, Sun L, Zheng H, Skaug B, Jiang QX, Chen ZJ. 2011. MAVS forms functional prion-like aggregates to activate and propagate antiviral innate immune response. Cell 146:448-61
78. Hsiao K, Baker HF, Crow TJ, Poulter M, Owen F, et al. 1989. Linkage of a prion protein missense variant to Gerstmann-Sträussler syndrome. Nature 338:342-45
79. Hsiao K, Chapman P, Nilsen S, Eckman C, Harigaya Y, et al. 1996. Correlative memory deficits, Aß elevation, and amyloid plaques in transgenic mice. Science 274:99-102
80. Hsiao K, Dlouhy S, Farlow MR, Cass C, Da Costa M, et al. 1992. Mutant prion proteins in Gerstmann-Sträussler-Scheinker disease with neurofibrillary tangles. Nat. Genet. 1:68-71
81. Hsiao KK, Groth D, Scott M, Yang S-L, Serban H, et al. 1994. Serial transmission in rodents of neurodegeneration from transgenic mice expressing mutant prion protein. Proc. Natl. Acad. Sci. USA 91:9126-30
82. Hsiao KK, Scott M, Foster D, Groth DF, DeArmond SJ, Prusiner SB. 1990. Spontaneous neurodegen-eration in transgenic mice with mutant prion protein. Science 250:1587-90
83. Hunter GD, Gibbons RA, Kimberlin RH, Millson GC. 1969. Further studies of the infectivity and stability of extracts and homogenates derived from scrapie affected mouse brains. J. Comp. Pathol. 79:101-8
84. Hutton M, Lendon CL, Rizzu P, Baker M, Froelich S, et al. 1998. Association of missense and 5-splice-site mutations in tau with the inherited dementia FTDP-17. Nature 393:702-5
85. Iba M, Guo JL, McBride JD, Zhang B, Trojanowski JQ, Lee VM. 2013. Synthetic tau fibrils mediate transmission of neurofibrillary tangles in a transgenic mouse model of Alzheimer's-like tauopathy. J. Neurosci. 33:1024-37
86. Irwin DJ, Abrams JY, Schonberger LB, Leschek EW, Mills JL, et al. 2013. Evaluation of potential infectivity of Alzheimer and Parkinson disease proteins in recipients of cadaver-derived human growth hormone. JAMA Neurol. 70:462-68
87. Johnson SM, Connelly S, Fearns C, Powers ET, Kelly JW. 2012. The transthyretin amyloidoses: from delineating the molecular mechanism of aggregation linked to pathology to a regulatory-agency-approved drug.J. Mol. Biol. 421:185-203
88. Johri A, Beal MF. 2012. Antioxidants in Huntington's disease. Biochim. Biophys. Acta 1822:664-74
89. Jonsson T, Atwal JK, Steinberg S, Snaedal J, Jonsson PV, et al. 2012. A mutation in APP protects against Alzheimer's disease and age-related cognitive decline. Nature 488:96-99
90. Jubelt B. 2004. Post-polio syndrome. Curr. Treat. Options Neurol. 6:87-93
91. Kaneko K, Ball HL, Wille H, Zhang H, Groth D, et al. 2000. A synthetic peptide initiates Gerstmann-Sträussler-Scheinker (GSS) disease in transgenic mice. J. Mol. Biol. 295:997-1007
92. Kfoury N, Holmes BB, Jiang H, Holtzman DM, Diamond MI. 2012. Trans-cellular propagation of tau aggregation by fibrillar species. J. Biol. Chem. 287:19440-51
93. Kimberlin RH, Walker CA. 1979. Pathogenesis of mouse scrapie: dynamics of agent replication in spleen, spinal cord and brain after infection by different routes. J. Comp. Pathol. 89:551-62
94. King C-Y, Tittman P, Gross H, Gebert R, Aebi M, Wüthrich K. 1997. Prion-inducing domain 2-114 of yeast Sup35 protein transforms in vitro into amyloid-like filaments. Proc. Natl. Acad. Sci. USA 94:6618-22
95. Klatzo I, Gajdusek DC, Zigas V. 1959. Pathology of kuru. Lab. Invest. 8:799-847
96. Kong Q, Surewicz WK, Petersen RB, Zou W, Chen SG, et al. 2004. Inherited prion diseases. In Prion Biology and Diseases, ed. SB Prusiner, pp. 673-775. Cold Spring Harbor, NY: Cold Spring Harbor Lab. Press
97. Korczyn AD, Vakhapova V, Grinberg LT. 2012. Vascular dementia. J. Neurol. Sci. 322:2-10
98. Kordower JH, Chu Y, Hauser RA, Freeman TB, Olanow CW. 2008. Lewy body-like pathology in long-term embryonic nigral transplants in Parkinson's disease. Nat. Med. 14:504-6
99. Kosik KS, Joachim CL, Selkoe DJ. 1986. Microtubule-associated protein tau is a major antigenic component of paired helical filaments in Alzheimer disease. Proc. Natl. Acad. Sci. USA 83:4044-48
100. Kumar N, Boeve BF, Boot BP, Orr CF, Duffy J, et al. 2011. Clinical characterization of a kindred with a novel 12-octapeptide repeat insertion in the prion protein gene. Arch. Neurol. 68:1165-70
101. Larsson N-G. 2010. Somatic mitochondrial DNA mutations in mammalian aging. Annu. Rev. Biochem. 79:683-706
102. Lee JM, Ramos EM, Lee JH, Gillis T, Mysore JS, et al. 2012. CAG repeat expansion in Huntington disease determines age at onset in a fully dominant fashion. Neurology 78:690-95
103. Legname G, Baskakov IV, Nguyen H-OB, Riesner D, Cohen FE, et al. 2004. Synthetic mammalian prions. Science 305:673-76
104. Legname G, Nguyen H-OB, Baskakov IV, Cohen FE, DeArmond SJ, Prusiner SB. 2005. Strain-specified characteristics of mouse synthetic prions. Proc. Natl. Acad. Sci. USA 102:2168-73
105. Legname G, Nguyen H-OB, Peretz D, Cohen FE, DeArmond SJ, Prusiner SB. 2006. Continuum of prion protein structures enciphers a multitude of prion isolate-specified phenotypes. Proc. Natl. Acad. Sci. USA 103:19105-10
106. Li J, Browning S, Mahal SP, Oelschlegel AM, Weissmann C. 2010. Darwinian evolution of prions in cell culture. Science 327:869-72
107. Li JY, Englund E, Holton JL, Soulet D, Hagell P, et al. 2008. Lewy bodies in grafted neurons in subjects with Parkinson's disease suggest host-to-graft disease propagation. Nat. Med. 14:501-3
108. Li M, Wang IX, Li Y, Bruzel A, Richards AL, et al. 2011. Widespread RNA and DNA sequence differences in the human transcriptome. Science 333:53-58
109. Liu L, Drouet V, Wu JW, Witter MP, Small SA, et al. 2012. Trans-synaptic spread of tau pathology in vivo. PLoS ONE 7:e31302
110. Luk KC, Kehm V, Carroll J, Zhang B, O'Brien P, et al. 2012. Pathological α-synuclein transmission initiates Parkinson-like neurodegeneration in nontransgenic mice. Science 338:949-53
111. Luk KC, Kehm VM, Zhang B, O'Brien P, Trojanowski JQ, Lee VMY. 2012. Intracerebral inoculation of pathological α-synuclein initiates a rapidly progressive neurodegenerative α-synucleinopathy in mice. J. Exp. Med. 209:975-86
112. Macario AJL, Conway de Macario E. 2005. Sick chaperones, cellular stress, and disease. N. Engl. J. Med. 353:1489-501
113. Mahley RW, Weisgraber KH, Huang Y. 2006. Apolipoprotein E4: a causative factor and therapeutic target in neuropathology, including Alzheimer's disease. Proc. Natl. Acad. Sci. USA 103:5644-51
114. Maji SK, Perrin MH, Sawaya MR, Jessberger S, Vadodaria K, et al. 2009. Functional amyloids as natural storage of peptide hormones in pituitary secretory granules. Science 325:328-32
115. Makarava N, Kovacs GG, Bocharova O, Savtchenko R, Alexeeva I, et al. 2010. Recombinant prion protein induces a new transmissible prion disease in wild-type animals. Acta Neuropathol. 119:177-87
116. Masters CL, Gajdusek DC, Gibbs CJ Jr. 1981. Creutzfeldt-Jakob disease virus isolations from the Gerstmann-Sträussler syndrome. Brain 104:559-88
117. Masters CL, Simms G, Weinman NA, Multhaup G, McDonald BL, Beyreuther K. 1985. Amyloid plaque core protein in Alzheimer disease and Down syndrome. Proc. Natl. Acad. Sci. USA 82:4245-49
118. Masuda-Suzukake M, Nonaka T, Hosokawa M, Oikawa T, Arai T, et al. 2013. Prion-like spreading of pathological α-synuclein in brain. Brain 136:1128-38
119. McKee AC, Stein TD, Nowinski CJ, Stern RA, Daneshvar DH, et al. 2013. The spectrum of disease in chronic traumatic encephalopathy. Brain 136:43-64
120. McKinley MP, Bolton DC, Prusiner SB. 1983. A protease-resistant protein is a structural component of the scrapie prion. Cell 35:57-62
121. McKinley MP, Braunfeld MB, Bellinger CG, Prusiner SB. 1986. Molecular characteristics of prion rods purified from scrapie-infected hamster brains. J. Infect. Dis. 154:110-20
122. Mead S. 2006. Prion disease genetics. Eur. J. Hum. Genet. 14:273-81
123. Medori R, Tritschler H-J, LeBlanc A, Villare F, Manetto V, et al. 1992. Fatal familial insomnia, a prion disease with a mutation at codon 178 of the prion protein gene. N. Engl. J. Med. 326:444-49
124. Meyer-Luehmann M, Coomaraswamy J, Bolmont T, Kaeser S, Schaefer C, et al. 2006. Exogenous induction of cerebral β-amyloidogenesis is governed by agent and host. Science 313:1781-84
125. Mills JL, Schonberger LB, Wysowski DK, Brown P, Durako SJ, et al. 2004. Long-term mortality in the United States cohort of pituitary-derived growth hormone recipients. J. Pediatr. 144:430-36
126. Morais VA, De Strooper B. 2010. Mitochondria dysfunction and neurodegenerative disorders: cause or consequence. J. Alzheimers Dis. 20:S255-63
127. Morales R, Duran-Aniotz C, Castilla J, Estrada LD, Soto C. 2012. De novo induction of amyloid-β deposition in vivo. Mol. Psychiatry 17:1347-53
128. Mori K, Weng SM, Arzberger T, May S, Rentzsch K, et al. 2013. The C9orf72 GGGGCC repeat is translated into aggregating dipeptide-repeat proteins in FTLD/ALS. Science 339:1335-38
129. Mougenot A-L, Nicot S, Bencsik A, Morignat E, Verchère J, et al. 2012. Prion-like acceleration of a synucleinopathy in a transgenic mouse model. Neurobiol. Aging 33:2225-28
130. Münch C, O'Brien J, Bertolotti A. 2011. Prion-like propagation of mutant superoxide dismutase-1 misfolding in neuronal cells. Proc. Natl. Acad. Sci. USA 108:3548-53
131. Nazor KE, Kuhn F, Seward T, Green M, Zwald D, et al. 2005. Immunodetection of disease-associated mutant Pr P, which accelerates disease in GSS transgenic mice. EMBO J. 24:2472-80
132. Oddo S, Caccamo A, Shepherd JD, Murphy MP, Golde TE, et al. 2003. Triple-transgenic model of Alzheimer's disease with plaques and tangles: intracellular Aβand synaptic dysfunction. Neuron 39:409-21
133. Okun MS. 2012. Deep-brain stimulation for Parkinson's disease. N. Engl. J. Med. 367:1529-38
134. Olanow CW, McNaught KS. 2006. Ubiquitin-proteasome system and Parkinson's disease. Mov. Disord. 21:1806-23
135. Olanow CW, Prusiner SB. 2009. Is Parkinson's disease a prion disorder? Proc. Natl. Acad. Sci. USA 106:12571-72
136. Omalu B, Hammers JL, Bailes J, Hamilton RL, Kamboh MI, et al. 2011. Chronic traumatic encephalopa-thy in an Iraqi war veteran with posttraumatic stress disorder who committed suicide. Neurosurg. Focus 31:E3
137. Omalu BI, DeKosky ST, Minster RL, Kamboh MI, Hamilton RL, Wecht CH. 2005. Chronic traumatic encephalopathy in a National Football League player. Neurosurgery 57:128-34
138. Peden A, McCardle L, Head MW, Love S, Ward HJ, et al. 2010. Variant CJD infection in the spleen of a neurologically asymptomatic UK adult patient with haemophilia. Haemophilia 16:296-304
139. Piro JR, Wang F, Walsh DJ, Rees JR, Ma J, Supattapone S. 2011. Seeding specificity and ultrastructural characteristics of infectious recombinant prions. Biochemistry 50:7111-16
140. Polymenidou M, Cleveland DW. 2012. Prion-like spread of protein aggregates in neurodegeneration. J. Exp. Med. 209:889-93
141. Polymeropoulos MH, Lavedan C, Leroy E, Ide SE, Dehejia A, et al. 1997. Mutation in the α-synuclein gene identified in families with Parkinson's disease. Science 276:2045-47
142. Poulter M, Baker HF, Frith CD, Leach M, Lofthouse R, et al. 1992. Inherited prion disease with 144 base pair gene insertion. 1. Genealogical and molecular studies. Brain 115:675-85
143. Prusiner SB. 1982. Novel proteinaceous infectious particles cause scrapie. Science 216:136-44
144. Prusiner SB. 1984. Some speculations about prions, amyloid, and Alzheimer's disease. N. Engl. J. Med. 310:661-63
145. Prusiner SB. 1989. Scrapie prions. Annu. Rev. Microbiol. 43:345-74
146. Prusiner SB. 2001. Shattuck lecture: neurodegenerative diseases and prions. N. Engl. J. Med. 344:1516-26
147. Prusiner SB. 2012. A unifying role for prions in neurodegenerative diseases. Science 336:1511-13
148. Prusiner SB, Cochran SP, Groth DF, Downey DE, Bowman KA, Martinez HM. 1982. Measurement of the scrapie agent using an incubation time interval assay. Ann. Neurol. 11:353-58
149. Prusiner SB, Groth DF, Cochran SP, Masiarz FR, McKinley MP, Martinez HM. 1980. Molecular properties, partial purification, and assay by incubation period measurements of the hamster scrapie agent. Biochemistry 21:4883-91
150. Prusiner SB, Hadlow WJ, Garfin DE, Cochran SP, Baringer JR, et al. 1978. Partial purification and evidence for multiple molecular forms of the scrapie agent. Biochemistry 17:4993-97
151. Prusiner SB, McKinley MP, Bowman KA, Bolton DC, Bendheim PE, et al. 1983. Scrapie prions aggregate to form amyloid-like birefringent rods. Cell 35:349-58
152. Prusiner SB, Scott M, Foster D, Pan K-M, Groth D, et al. 1990. Transgenetic studies implicate interactions between homologous PrP isoforms in scrapie prion replication. Cell 63:673-86
153. Rabinovici GD, Miller BL. 2010. Frontotemporal lobar degeneration: epidemiology, pathophysiology, diagnosis and management. CNS Drugs 24:375-98
154. Rademakers R, Baker M, Gass J, Adamson J, Huey ED, et al. 2007. Phenotypic variability associated with progranulin haploinsufficiency in patients with the common 1477C→T (Arg493X) mutation: an international initiative. Lancet Neurol. 6:857-68
155. Rademakers R, Neumann M, Mackenzie IR. 2012. Advances in understanding the molecular basis of frontotemporal dementia. Nat. Rev. Neurol. 8:423-34
156. Ravits JM, La Spada AR. 2009. ALS motor phenotype heterogeneity, focality, and spread: deconstructing motor neuron degeneration. Neurology 73:805-11
157. Ren PH, Lauckner JE, Kachirskaia I, Heuser JE, Melki R, Kopito RR. 2009. Cytoplasmic penetration and persistent infection of mammalian cells by polyglutamine aggregates. Nat. Cell Biol. 11:219-25
158. Ridley RM, Baker HF, Windle CP, Cummings RM. 2006. Very long term studies of the seeding of β-amyloidosis in primates. J. Neural Transm. 113:1243-51
159. Roberson ED, Scearce-Levie K, Palop JJ, Yan F, Cheng IH, et al. 2007. Reducing endogenous tau ameliorates amyloid β-induced deficits in an Alzheimer's disease mouse model. Science 316:750-54
160. Rogers DR. 1965. Screening for amyloid with the thioflavin-t fluorescent method. Am. J. Clin. Pathol. 44:59-61
161. Roos R, Gajdusek DC, Gibbs CJ Jr. 1973. The clinical characteristics of transmissible Creutzfeldt-Jakob disease. Brain 96:1-20
162. Rosen RF, Fritz JJ, Dooyema J, Cintron AF, Hamaguchi T, et al. 2012. Exogenous seeding of cerebral β-amyloid deposition in βAPP-transgenic rats. J. Neurochem. 120:660-66
163. Safar JG, Kellings K, Serban A, Groth D, Cleaver JE, et al. 2005. Search for a prion-specific nucleic acid. J. Virol. 79:10796-806
164. Schellenberg GD, Bird TD, Wijsman EM, Orr HT, Anderson L, et al. 1992. Genetic linkage evidence for a familial Alzheimer's disease locus on chromosome 14. Science 258:668-71
165. Schellenberg GD, Montine TJ. 2012. The genetics and neuropathology of Alzheimer's disease. Acta Neuropathol. 124:305-23
166. Scott JR, Davies D, Fraser H. 1992. Scrapie in the central nervous system: neuroanatomical spread of infection and Sinc control of pathogenesis. J. Gen. Virol. 73:1637-44
167. Seeley WW, Crawford RK, Zhou J, Miller BL, Greicius MD. 2009. Neurodegenerative diseases target large-scale human brain networks. Neuron 62:42-52
168. Selkoe DJ. 2011. Resolving controversies on the path to Alzheimer's therapeutics. Nat. Med. 17:1060-65
169. Shimizu S, Hoshi K, Muramoto T, Homma M, Ironside JW, et al. 1999. Creutzfeldt-Jakob disease with florid-type plaques after cadaveric dura mater grafting. Arch. Neurol. 56:357-62
170. Si K, Choi YB, White-Grindley E, Majumdar A, Kandel ER. 2010. Aplysia CPEB can form prion-like multimers in sensory neurons that contribute to long-term facilitation. Cell 140:421-35
171. Si K, Lindquist S, Kandel ER. 2003. A neuronal isoform of the aplysia CPEB has prion-like properties. Cell 115:879-91
172. Silveira JR, Raymond GJ, Hughson AG, Race RE, Sim VL, et al. 2005. The most infectious prion protein particles. Nature 437:257-61
173. +] factor by in vitro-converted Sup35 protein. Science 289:595-99
174. Spillantini MG, Schmidt ML, Lee VM-Y, Trojanowski JQ, Jakes R, Goedert M. 1997. α-Synuclein in Lewy bodies. Nature 388:839-40
175. Spudich S, Mastrianni JA, Wrensch M, Gabizon R, Meiner Z, et al. 1995. Complete penetrance of Creutzfeldt-Jakob disease in Libyan Jews carrying the E200K mutation in the prion protein gene. Mol. Med. 1:607-13
176. St. George-Hyslop P, Haines J, Rogaev E, Mortilla M, Vaula G, et al. 1992. Genetic evidence for a novel familial Alzheimer's disease locus on chromosome 14. Nat. Genet. 2:330-34
177. St. George-Hyslop PH. 1999. Molecular genetics of Alzheimer disease. In Alzheimer Disease, ed. RD Terry, R Katzman, KL Bick, SS Sisodia, pp. 311-26. Philadelphia: Lippincott Williams & Wilkins. 2nd ed.
178. Stevens DJ, Walter ED, Rodriguez A, Draper D, Davies P, et al. 2009. Early onset prion disease from octarepeat expansion correlates with copper binding properties. PLoS Pathog. 5:e1000390
179. Stöhr J, Watts JC, Mensinger ZL, Oehler A, Grillo SK, et al. 2012. Purified and synthetic Alzheimer's amyloid beta (Aβ) prions. Proc. Natl. Acad. Sci. USA 109:11025-30
180. Tamgüney G, Francis KP, Giles K, Lemus A, DeArmond SJ, Prusiner SB. 2009. Measuring prions by bioluminescence imaging. Proc. Natl. Acad. Sci. USA 106:15002-6
181. Tamgüney G, Giles K, Bouzamondo-Bernstein E, Bosque PJ, Miller MW, et al. 2006. Transmission of elk and deer prions to transgenic mice. J. Virol. 80:9104-14
182. Taraboulos A, Jendroska K, Serban D, Yang S-L, DeArmond SJ, Prusiner SB. 1992. Regional mapping of prion proteins in brains. Proc. Natl. Acad. Sci. USA 89:7620-24
183. Tatzelt J, Groth DF, Torchia M, Prusiner SB, DeArmond SJ. 1999. Kinetics of prion protein accumulation in the CNS of mice with experimental scrapie. J. Neuropathol. Exp. Neurol. 58:1244-49
184. The Huntington's Disease Collaborative Research Group. 1993. A novel gene containing a trinucleotide repeat that is expanded and unstable on Huntington's disease chromosomes. Cell 72:971-83
185. Toyama BH, Kelly MJ, Gross JD, Weissman JS. 2007. The structural basis of yeast prion strain variants. Nature 449:233-37
186. Toyama BH, Weissman JS. 2011. Amyloid structure: conformational diversity and consequences. Annu. Rev. Biochem. 80:557-85
187. Tracey KJ. 2009. Reflex control of immunity. Nat. Rev. Immunol. 9:418-28
188. Sc conformers induced by a synthetic peptide and several prion strains. J. Virol. 78:2088-99
189. Udan M, Baloh RH. 2011. Implications of the prion-related Q/N domains in TDP-43 and FUS. Prion 5:1-5
190. Valentine JS, Doucette PA, Zittin Potter S. 2005. Copper-zinc superoxide dismutase and amyotrophic lateral sclerosis. Annu. Rev. Biochem. 74:563-93
191. van der Kamp MW, Daggett V. 2009. The consequences of pathogenic mutations to the human prion protein. Protein Eng. Des. Sel. 22:461-68
192. Volpicelli-Daley LA, Luk KC, Patel TP, Tanik SA, Riddle DM, et al. 2011. Exogenous α-synuclein fibrils induce Lewy body pathology leading to synaptic dysfunction and neuron death. Neuron 72:57-71
193. Walsh DM, Selkoe DJ. 2007. Aβ oligomers: a decade of discovery. J. Neurochem. 101:1172-84
194. Wang F, Wang X, Yuan C-G, Ma J. 2010. Generating a prion with bacterially expressed recombinant prion protein. Science 327:1132-35
195. Watts JC, Giles K, Grillo SK, Lemus A, DeArmond SJ, Prusiner SB. 2011. Bioluminescence imaging of Aβdeposition in bigenic mouse models of Alzheimer's disease. Proc. Natl. Acad. Sci. USA 108:2528-33
196. Watts JC, Giles K, Stöhr J, Oehler A, Bhardwaj S, et al. 2012. Spontaneous generation of rapidly transmissible prions in transgenic mice expressing wild-type bank vole prion protein. Proc. Natl. Acad. Sci. USA 109:3498-503
197. Wheeler VC, Gutekunst CA, Vrbanac V, Lebel LA, Schilling G, et al. 2002. Early phenotypes that presage late-onset neurodegenerative disease allow testing of modifiers in Hdh CAG knock-in mice. Hum. Mol. Genet. 11:633-40
198. Wickner RB. 1994. [URE3] as an altered URE2 protein: evidence for a prion analog in Saccharomyces cerevisiae. Science 264:566-69
199. Wickner RB, Edskes HK, Shewmaker F, Nakayashiki T. 2007. Prions of fungi: inherited structures and biological roles. Nat. Rev. Microbiol. 5:611-18
200. Wille H, Bian W, McDonald M, Kendall A, Colby DW, et al. 2009. Natural and synthetic prion structure from x-ray fiber diffraction. Proc. Natl. Acad. Sci. USA 106:16990-95
201. Wood JG, Mirra SS, Pollock NJ, Binder II. 1986. Neurofibrillary tangles of Alzheimer's disease share antigenic determinants with the axonal microtubule-associated protein tau. Proc. Natl. Acad. Sci. USA 83:4040-43
202. Yuan J, Yankner BA. 2000. Apoptosis in the nervous system. Nature 407:802-9
203. Zhou J, Gennatas ED, Kramer JH, Miller BL, Seeley WW. 2012. Predicting regional neurodegeneration from the healthy brain functional connectome. Neuron 73:1216-27
204. Zilber N, Rannon L, Alter M, Kahana E. 1983. Measles, measles vaccination, and risk of subacute sclerosing panencephalitis (SSPE). Neurology 33:1558-64
205. Zobeley E, Flechsig E, Cozzio A, Enari M, Weissmann C. 1999. Infectivity of scrapie prions bound to a stainless steel surface. Mol. Med. 5:240-43